SAN FRANCISCO, Nov. 17, 2011 /PRNewswire/ -- Caliper® Life Sciences, a Perkin-Elmer Company, launched their new Vectra™ 2 with AQUA technology, an integrated solution for quantification of protein biomarkers in tissue, at the Molecular Targets & Cancer Therapeutics meeting here this week. Caliper and HistoRx® collaborated on this new immunofluorescent imaging and analysis solution that will deliver objective, quantitative, and reproducible results: an improvement on traditional immunohistochemistry. The new product enables users to leverage the combined imaging and analysis power of Caliper's Vectra 2, an automated multiplexed and multispectral tissue imaging platform, and AQUA® technology, HistoRx's proprietary image analysis system, to provide an integrated solution to advance the identification and validation of new drug targets and improve assessment of drug response.
"The Vectra 2 with AQUA technology represents a significant move forward for those interested in digital pathology with both brightfield and fluorescent capabilities," said Mark Gustavson, Ph.D., Director of Operations at HistoRx. "By matching AQUA technology's fluorescence-based quantitative measurement with Caliper's market-leading multispectral imaging capabilities, users will be afforded a level of quality, performance and reproducibility that is unparalleled. Caliper has outdone itself with enhancements to its earlier product, while HistoRx has ensured that customer needs for high-volume digital fluorescence analysis are addressed through AQUAServe™."
AQUAServe is a new server-based queuing software designed to enable 'walk-away' operation for multiple specimens while retaining the full functionality of HistoRx's flagship AQUAnalysis™ software. AQUAServe will enable high-volume customers to take full advantage of Vectra's 200-slide loader. Caliper will distribute the integrated product in the research market; the companies are also exploring collaborations in clinical research and diagnostics. Caliper and Vectra are trademarks of Caliper Life Sciences.
About HistoRx, Inc.
HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care. The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA technology. AQUA technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, reproducible, and automated analysis to guide drug development and therapeutic decision-making. HistoRx is commercializing proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care. AQUA is a registered trademark of HistoRx, Inc. For more information, please visit www.historx.com.
|SOURCE HistoRx, Inc.|
Copyright©2010 PR Newswire.
All rights reserved